- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Aptivus
Synonyms :
tipranavir
Class :
Antiviral agents and Anti-HIV (Protease inhibitor)
Dosage Forms & Strengths
Solution, Oral:
100 mg/ml
Capsule, Oral:
250 mg
500
mg
Orally
twice a day
Capsule
in combination with ritonavir (200 mg)
Dosage Forms & Strengths
Solution, Oral:
100 mg/ml
Capsule, Oral:
250 mg
Children >2 years:
14
mg/kg
in combination with 6 mg/kg ritonavir twice a day (NMT 500 mg)
Refer to adult dosing
tipranavir: they may enhance serum concentrations of rifabutin
when both drugs are combined, there may be an increased risk of adverse effects
may enhance the concentration of serum when combined with salmeterol
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
It may enhance when combined with oxycodone by affecting CYP3A4 metabolism
when both drugs are combined, there may be a reduced metabolism of erlotinib
the effect of tipranavir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of tipranavir by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tipranavir
tipranavir increases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may decrease the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the serum concentration
may enhance the serum concentration of elbasvir/grazoprevir
may enhance the serum concentration when combined
Tipranavir may enhance the therapeutic concentration of cabozantinib
May decrease the therapeutic effects of cladribine
May enhance the plasma concentration of CYP3A4 substrates
May enhance the plasma concentration of CYP3A4 substrates
May enhance the plasma concentration of CYP3A4 substrates
May enhance the plasma concentration of CYP3A4 substrates
May reduce the therapeutic efficacy of tipranavir
May reduce the therapeutic efficacy of tipranavir
May reduce the plasma concentration of antiretroviral agents
May enhance the therapeutic concentration of tipranavir
Coadministration of tipranavir with warfarin can increase the risk of bleeding or unusual bleeding
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
tipranavir: they may increase the antiplatelet effect of antiplatelet properties
tipranavir: they may increase the antiplatelet effect of antiplatelet properties
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
may increase the anti-coagulant action of anti-coagulants
It may enhance toxicity when combined with cholic acid by diminishing the elimination
may diminish the serum concentration of each other when combined
metronidazole (Topical): they may increase the adverse effect of tipranavir
tipranavir, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism ixaz
Frequency defined:
>10%
Skin rash
Vomiting
Bronchitis
Cough
Upper respiratory tract infection
Fever
1% to 10%:
Acute myocardial infection
Cardiac failure
Coronary artery disease
Coronary occlusion
Endocarditis
Hypertension
Ischemic heart disease
Portal vein thrombosis
Septic shock
Unstable angina pectoris
Acne vulgaris
Alopecia
Folliculitis
Nail disease
Pruritis
Sweat gland disease
Lipodystrophy
Frequency not defined:
Hepatitis
Hepatotoxicity
Immune reconstitution syndrome
Post-marketing:
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Drug rash with eosinophilia
Pregnancy consideration: Tipranavir may transfer in moderate to high amounts across the human placenta.
Lactation: excretion of tipranavir in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Tipranavir
Pronunciation: tipranavir
Why do we use Tipranavir?
It is used to treat viral infections such as HIV infection.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
